FIELD: medicine.
SUBSTANCE: substance of invention involves specific chimeric and humanised antibodies, nucleic acids, encoding amino acid sequences of heavy and light immunoglobulin chains, vectors expressing these nucleic acids, as well as to method for antibody purification.
EFFECT: development of preparation for angiogenesis decrease.
30 cl, 6 ex, 26 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF ANTIBODIES AGAINST α5β1 FOR INHIBITION OF CANCER CELLS PROLIFERATION | 2005 |
|
RU2361614C2 |
| NOVEL ANTIBODIES | 2008 |
|
RU2490277C2 |
| ALPHA5-BETA 1 ANTIBODIES AND USING THEM | 2009 |
|
RU2528736C2 |
| ALPHA-V BETA-8-BINDING ANTIBODIES | 2012 |
|
RU2614252C2 |
| COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES | 2010 |
|
RU2569109C2 |
| INTEGRIN β1 ANTIBODY COMPOSITIONS AND METHODS FOR USE THEREOF | 2013 |
|
RU2681994C2 |
| ANTIBODY IGG WITH AFFINITY BINDING WITH RESPECT TO ANTIGENIC COMPLEX CD3, RECOMBINANT NUCLEIC ACIDS ENCODING ANTIBODY LIGHT AND HEAVY CHAIN, METHOD FOR PREPARING SYSTEM, METHOD FOR PREPARING ANTIBODY, METHOD FOR TREATMENT OF PATIENT | 1999 |
|
RU2244720C2 |
| ANTIBODY AGAINST LAG-3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR PHARMACEUTICAL APPLICATION | 2017 |
|
RU2757813C2 |
| HUMANISED ANTI-BETA 7 ANTAGONISTIC ANTIBODIES AND USE THEREOF | 2005 |
|
RU2453558C2 |
| HUMANISED ANTI c-met ANTAGONISTS | 2005 |
|
RU2398777C2 |
